Angiotensin II in experimental hyperdynamic sepsis
Li Wan, Christoph Langenberg, Rinaldo Bellomo, Clive N May
CRITICAL CARE | BMC | Published : 2009
INTRODUCTION: Angiotensin II (Ang II) is a potential vasopressor treatment for hypotensive hyperdynamic sepsis. However, unlike other vasopressors, its systemic, regional blood flow and renal functional effects in hypotensive hyperdynamic sepsis have not been investigated. METHODS: We performed an experimental randomised placebo-controlled animal study. We induced hyperdynamic sepsis by the intravenous administration of live E. coli in conscious ewes after chronic instrumentation with flow probes around the aorta and the renal, mesenteric, coronary and iliac arteries. We allocated animals to either placebo or angiotensin II infusion titrated to maintain baseline blood pressure. RESULTS: Hype..View full abstract
Related Projects (3)
Awarded by NHMRC
The authors are grateful to Craig Thomson (Funded by Howard Florey Institute) for excellent technical assistance. The study was supported by NHMRC Project grant No 454615. This study was also supported by grant from the Australian and New Zealand College of Anaesthetists and from the Intensive Care Foundation. CNM was supported by NHMRC Research Fellowships No 350328 and 566819. Dr C. Langenberg was funded by Else Kroner-Fresenius Foundation (Germany).